FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pfizer | Wyeth | Patent | Generic drugs | Effexor XR | Mylan

Mylan, Wyeth ink Effexor agreements

Mylan Pharmaceuticals has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to venlafaxine HCl ER capsules in 37.5-, 75- and 150-mg strengths. The product is the generic version of Wyeth's Effexor XR capsules, a treatment for major depressive disorder. Mylan will be granted a non-exclusive license to the relevant patents that would permit it to launch the capsules in the U.S. on or after June 1, 2011--or earlier in limited circumstances. Additional details of the agreement remain confidential. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Pfizer   Wyeth   Patent   Generic drugs   Effexor XR   Mylan